폐암 시장 규모, 점유율, 성장 분석 : 진단·치료별, 적응증별, 최종 용도별, 지역별 - 산업별 예측(2024-2031년)
Lung Cancer Market Size, Share, Growth Analysis, By Diagnostics & Therapy (Diagnostics, Therapy), By Indication (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), By End-Use, By Region - Industry Forecast 2024-2031
상품코드:1619188
리서치사:SkyQuest
발행일:2024년 12월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 폐암 시장 규모는 2022년에 294억 5,000만 달러로 평가되며, 2023년 326억 6,000만 달러에서 2031년에는 747억 3,000만 달러로 성장하며, 예측 기간(2024-2031년)의 CAGR은 10.9%로 성장할 전망입니다.
세계의 폐암 시장은 공중위생에 중대한 과제를 초래하는 유행하고 있는 치사적인 질환의 진단, 치료, 관리에 초점을 맞춘 중요한 헬스케어 분야입니다. 주로 흡연, 환경오염 물질, 유전적 요인에 기인하는 이환율의 상승에 수반하여 표적치료 및 면역치료 등 진단·치료 옵션의 혁신적 진보가 시장을 지원하고 있습니다. 기존 화학요법에서 개별화된 효과적인 치료법으로의 전환이 환자 예후를 개선하는 한편, 조기 발견 및 예방 조치에 대한 인식이 높아짐에 따라 시장 성장을 가속하고 있습니다. 치료 비용과 접근성 등의 문제에도 불구하고 인공지능과 빅데이터의 통합과 함께 진행 중인 연구는 진단 및 치료 전략에 혁명을 일으킬 것으로 기대되며, 이 진화하는 시장에서 환자 치료 개선과 성장의 큰 잠재력을 보여주고 있습니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요의 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2023년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
기술 분석
규제 분석
특허 분석
사례 연구 분석
파이프라인 분석
폐암 시장 규모 : 진단·치료별 및 CAGR(2024-2031년)
시장 개요
진단
기관지경 검사
TTNA
이미징
종양 바이오마커 검사
In Situ 하이브리다이제이션
기타
치료
비침습적
면역치료
표적치료
저침습
고주파 절제
마이크로파 절제
열응고/냉동요법
폐암 시장 규모 : 적응증별 및 CAGR(2024-2031년)
시장 개요
비스몰셀 폐암
스몰셀 폐암
폐암 시장 규모 : 최종 용도별 및 CAGR(2024-2031년)
시장 개요
병원
진단 검사실
영상 진단 센터
학술계
전문 클리닉
폐암 시장 규모 및 CAGR(2024-2031년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2023년)
주요 시장 기업이 채택한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2023년)
주요 기업의 기업 개요
회사 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출의 전년대비 비교(2021-2023년)
주요 기업 개요
F. Hoffmann-La Roche(Switzerland)
AstraZeneca(UK)
Sanofi(France)
Pfizer, Inc.(US)
Bristol-Myers Squibb Company(US)
Sysmex Corporation(Japan)
Thermo Fisher Scientific(US)
Qiagen(Germany)
Janssen Pharmaceuticals(US)
Quest Diagnostics(US)
Takeda Pharmaceutical Company(Japan)
Novartis AG(Switzerland)
Eli Lilly & Company(US)
Merck & Co., Inc.(US)
Boehringer Ingelheim(Germany)
Merck KGaA(EMD Serono)(Germany)
AbbVie(US)
Astellas Pharma(Japan)
GlaxoSmithKline(UK)
Johnson & Johnson(US)
결론과 권장사항
KSA
영문 목차
영문목차
Global Lung Cancer Market size was valued at USD 29.45 billion in 2022 and is poised to grow from USD 32.66 billion in 2023 to USD 74.73 billion by 2031, growing at a CAGR of 10.9% during the forecast period (2024-2031).
The global lung cancer market represents a vital healthcare sector focused on diagnosing, treating, and managing a prevalent and lethal disease that poses significant public health challenges. With rising incidences primarily attributed to smoking, environmental pollutants, and genetic factors, the market is fueled by innovative advancements in diagnostic and therapeutic options, such as targeted therapies and immunotherapies. A notable shift from traditional chemotherapy to personalized and effective treatments enhances patient outcomes, while increased awareness of early detection and preventative measures drives market growth. Despite challenges like treatment costs and accessibility, ongoing research, alongside the integration of artificial intelligence and big data, promises to revolutionize diagnosis and therapeutic strategies, showcasing significant potential for improved patient care and growth within this evolving market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Lung Cancer Market Segmental Analysis
Global Lung Cancer Market is segmented by diagnostics, indication, end-use and region. Based on diagnostics, the market is segmented into diagnostics and therapy. Based on indication, the market is segmented into non-small cell lung cancer and small cell lung cancer. Based on end-use, the market is segmented into hospitals, diagnostic laboratories, diagnostic imaging centers, academia, specialty clinics, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Lung Cancer Market
A significant catalyst for the global lung cancer market is the relentless progress in medical research and technology. The growing comprehension of lung cancer biology, alongside breakthroughs in diagnostic tools, targeted therapies, immunotherapies, and precision medicine, is propelling market growth. These innovations not only introduce novel treatment alternatives but also enhance patient outcomes and facilitate early detection. The shift towards personalized treatment strategies allows healthcare providers to tailor interventions to individual patient profiles, further driving the demand for advanced lung cancer therapies. Consequently, these technological advancements are pivotal in shaping the future landscape of the lung cancer treatment market.
Restraints in the Global Lung Cancer Market
One of the main challenges facing the global lung cancer market is the exorbitant cost associated with treatments. Patients often confront substantial financial burdens due to the high prices of lung cancer therapies, such as targeted treatments and immunotherapies. This issue can severely limit patient access to these advanced options, particularly in areas with limited healthcare resources or insufficient insurance coverage. Consequently, the overall affordability and accessibility of lung cancer treatments create significant obstacles that can impede the market's growth and hinder the provision of equitable care to patients, ultimately affecting the broader adoption of essential therapies.
Market Trends of the Global Lung Cancer Market
The global lung cancer market is witnessing a significant trend towards precision medicine and targeted therapies, driven by advancements in genomic research and molecular characterization of tumors. This shift fosters the development of personalized treatment regimens that specifically address genetic mutations and biomarkers unique to each patient. As healthcare systems prioritize improved treatment outcomes and reduced adverse effects, the demand for tailored therapies is surging. Furthermore, the integration of molecular profiling techniques is enhancing the efficacy of treatments, promising better patient care and prognosis. This evolution not only reshapes therapeutic approaches but also amplifies the potential for innovation in lung cancer management globally.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Regulatory Analysis
Patent Analysis
Case Study Analysis
Pipeline Analysis
Global Lung Cancer Market Size by Diagnostics & Therapy & CAGR (2024-2031)
Market Overview
Diagnostics
Bronchoscopy
TTNA
Imaging
Tumor Biomarker Test
In Situ Hybridization
Others
Therapy
Non-Invasive
Immunotherapy
Targeted Therapy
Minimally Invasive
Radiofrequency Ablation
Microwave Ablation
Thermal/Cryoablation
Global Lung Cancer Market Size by Indication & CAGR (2024-2031)
Market Overview
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Global Lung Cancer Market Size by End-Use & CAGR (2024-2031)
Market Overview
Hospitals
Diagnostic Laboratories
Diagnostic Imaging Centers
Academia
Specialty Clinics
Global Lung Cancer Market Size & CAGR (2024-2031)
North America (Diagnostics & Therapy, Indication, End-Use)
USA
Canada
Europe (Diagnostics & Therapy, Indication, End-Use)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Diagnostics & Therapy, Indication, End-Use)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Diagnostics & Therapy, Indication, End-Use)
Brazil
Rest of Latin America
Middle East & Africa (Diagnostics & Therapy, Indication, End-Use)
